Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Nom du journal : Haematologica
Année : 2024
Volume : 109
Page de départ : 1857-1865
